• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 12th May 2020

Indication-Based Pricing: Are We All Onboard?

A move towards paying multiple prices for medicines (depending on what they are used for) could address a commonly cited problem in drug development and increase patient access. Our latest consulting report investigates whether key stakeholders are onboard. A move…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

A move towards paying multiple prices for medicines (depending on what they are used for) could address a commonly cited problem in drug development and increase patient access. Our latest consulting report investigates whether key stakeholders are onboard.

A move towards paying multiple prices for medicines (depending on what they are used for) could address a commonly cited problem in drug development and increase patient access. Our latest consulting report investigates whether key stakeholders are onboard.

Policy change requires constructive conversation and a shared understanding of key issues. Beyond that, policy change requires alignment among key stakeholders and – ultimately – it requires buy-in. In a report published today, we investigate whether there is buy-in for indication-based pricing (IBP).

What is the issue?

The price we pay for medicines should: be aligned with the value medicines provide to patients and the health service; be affordable; and offer a fair reward (and therefore incentive) to developers. However, we are increasingly discovering that individual medicines can be useful in many different and diverse scenarios or patient groups (‘indications’). One medicine normally has one price, so how do we make sure we are paying the ‘right’ price across all these indications? (Where a ‘wrong’ price leads to some patients not accessing potentially beneficial treatments.)

Is IBP the solution?

As more and more medicines come to market with multiple indications (or even more importantly, the unrealised potential to treat multiple indications), the way we pay for those medicines becomes critical in making sure we can benefit from them. ‘Indication-based pricing’ (IBP) permits price to vary according to indication and has been proposed as a solution to meeting this challenge.

In previous publications the OHE has outlined and critically evaluated the academic debate around IBP and how it has been implemented, as well as the economic arguments for/against IBP in terms of impacts on payer budgets, patient access and incentives for innovation. Last year we published a short Discussion Paper on IBP which laid out the key issues with the aim of promoting a shared understanding. This was accompanied by a questionnaire (also translated to Spanish and French) eliciting stakeholders’ thoughts around the positives, the pitfalls and the practicalities of IBP. Through this stakeholder consultation exercise – funded by AstraZeneca and published today – we are able to outline what stakeholders think.

What do stakeholders think?

Sixteen countries were represented among the 73 survey respondents, who among others included representatives of industry, payers, regulators and academics.

Most respondents agreed that some form of IBP would be a good thing (78%) although this belief was held most strongly by industry (96%) and regulators (83%), and less strongly by payers (65%) and academics (57%). Encouragingly, those with experience of IBP were more positive than those without.

70% of survey respondents believed IBP would expand patient access to medicines. However, three-quarters of respondents believed that expanded patient access via IBP would put pressure on payer budgets, although a subset believed that in the long run IBP will generate competition and lead to lower prices.

There was a wide spread of opinion on the best way to implement IBP, the most popular options being a single price based on a weighted average of value and usage across indications, and differential list prices aligned with value for each indication; another popular suggestion (and potentially the most practical) was to have a single price with confidential differential discounts by indication.

Significant barriers to IBP were considered to be inadequate data infrastructure (in particular capturing actual usage by indication), and the perception that IBP is not currently a policy priority in most countries.

Is there buy-in?

Buy-in requires that stakeholders understand the benefits and see the gains. There was a spread of opinion about who is the biggest “winner” from IBP. More than half of respondents (57%) thought that all stakeholders could gain from IBP. However, 31% considered industry to be the single stakeholder that stood to gain the most from IBP. This helps to explain respondents’ view that there was a lack of stakeholder buy-in to pursing IBP, hence a lack of political will to implement it. Our earlier Discussion Paper indicated that the mechanism for the benefit to industry – stimulation of R&D by better aligning price and value at the indication-level – paved the way for expanded patient access. The fact that patients were not singled out as the biggest winner by survey respondents remains a major challenge to achieving greater support for IBP. 

Related Research

Cole, A., Towse, A. & Zamora, B., 2019. Indication-Based Pricing (IBP) Discussion Paper. OHE Briefing, London: Office of Health Economics. Available at: https://www.ohe.org/publications/indication-based-pricing-ibp-discussion-paper-should-drug-pricesdiffer-indication

Cole, A., Towse, A., Lorgelly, P. and Sullivan, R. (2018). Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals. OHE Research Paper 18/04, London: Office of Health Economics. Available at: https://www.ohe.org/publications/economics-innovative-payment-models-comparedsingle-pricing-pharmaceuticals#overlay-context=publications

Towse, A., Cole, A., and Zamora, B. (2018). The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries. OHE Consulting Report, London: Office of Health Economics. Available at: https://www.ohe.org/publications/debate-indicationbased-pricing-us-and-five-major-european-countries

Neri, M., Towse, A. and Garau, M. (2018). Value Assessment of Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward. OHE Briefing, London: Office of Health Economics. Available at: https://www.ohe.org/publications/multi-indication-pricing-mip-practical-solutions-and-steps-move-forward#

Mestre-Ferrandiz,J., Towse, A., Dellamano, R., and Pistollato, M. (2015). Multi-indication Pricing: Pros, Cons and Applicability to the UK. Seminar Briefing 56. Office of Health Economics. Available at: https://www.ohe.org/publications/multi-indication-pricing-pros-cons-and-applicability-uk

 

  • Value-Based Pricing
  • Economics of Innovation
  • Consulting Reports

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!